Abstract
The androgen dihydrotestosterone is synthesized by the enzyme steroid 5α- reductase, and it is required for growth and development of the prostate. We used immunohistochemistry to examine the expression of the type 2 isozyme of 5α-reductase in benign prostatic hyperplasia and prostate cancer. The type 2 isozyme is highly expressed within stromal cells in both disease states. No type 2 isozyme is detectable in a lymph node metastasis. Immunoblotting studies show that androgen ablation therapies substantially decrease isozyme expression in the epididymis but have a lesser effect on expression in the prostate. Finasteride therapy (2 weeks to 3 years) did not abolish expression of the prostatic type 2 isozyme nor did this drug treatment induce expression of the type 1 isozyme.
Original language | English (US) |
---|---|
Pages (from-to) | 433-437 |
Number of pages | 5 |
Journal | Journal of Urology |
Volume | 152 |
Issue number | 2 |
DOIs | |
State | Published - 1994 |
Keywords
- androgens
- antiandrogens
- dihydrotestosterone
- prostatic hypertrophy
- prostatic neoplasms
ASJC Scopus subject areas
- Urology